Пумпан

Quick links to important sections

Пумпан

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Пумпан

Property Description
Active ingredients Arnica montana, Convallaria majalis, Crataegus, Digitalis purpurea, Kalium Carbonicum
Form Oral Drops (Solution) and Tablets
Pharmacological class Complex Homeopathic Preparation, Cardiotonic, Circulatory Regulator
Common use Supportive function for the cardiovascular system
Origin Natural-derived (Botanical and Mineral)

Пумпан is defined as a multi-component complex homeopathic medicinal product officially classified as a cardiotonic and circulatory regulator intended for supportive use within the cardiovascular system. Its composition comprises a fixed combination of five active substances, which is a key differentiating factor from many single-component preparations. This formulation approach is intended for delivering a comprehensive, stabilizing effect across various physiological targets within the circulation.

What Type of Preparation is Пумпан?

The classification of Пумпан as a complex homeopathic preparation indicates that the formula consists of multiple ingredients prepared in low-dose potencies. The inclusion of components like Crataegus (Hawthorn) is linked to traditional supportive functions for cardiac muscle and circulatory efficiency. The inclusion of these botanicals is supported by documented traditional use for cardiotonic support of heart function, making it a typical choice for individuals seeking to maintain general heart and vascular tone.

Composition: What Ingredients and Forms Define Пумпан?

The active composition of Пумпан is defined by five distinct, low-dose ingredients derived from both botanical and mineral origins. The formula integrates the plant-derived substances Arnica D6, Convallaria D12, Crataegus D1, and Digitalis D12, alongside the mineral compound Kalium Carbonicum D6. A key differentiating feature is the availability of the drug for oral administration in two distinct dosage forms: oral drops (a hydro-alcoholic solution) and solid tablets (based on lactose excipients).

What is the General Purpose of the Circulatory Regulator?

The general purpose of this multi-component regulator is to offer supportive and stabilizing effects specifically for the circulatory network. Traditional pharmacological literature discusses the constituents, such as Convallaria majalis, for their use in contributing to healthy cardiac output and vascular tone. This indicates the medicine’s design is intended to contribute to the functional capacity and stability of the heart and blood vessels. By combining principles intended for cardiotonic, vascular, and metabolic support, the preparation is utilized to generally contribute to overall functional health.

Regulatory References

  1. Hawthorn: Usefulness and Safety | NCCIH

What side effects are possible with Пумпан?

Possible Side Effects and Safety Information

The safety profile of this multi-component preparation is officially defined by high-level regulatory statements, consistent with its classification as a complex homeopathic medicinal product. The documented adverse reaction profile focuses primarily on the potential for allergic events and specific formulation constraints.

Adverse Reactions and Regulatory Classification

The most commonly documented adverse reactions involve the immune system and the skin. These are classified in regulatory documents as hypersensitivity reactions (allergic manifestations) to the active ingredients or to the excipients.

Classification Feature Official Regulatory Statement
Adverse Reaction Category Hypersensitivity Reactions
System-Organ Class (SOC) Immune System and Skin Disorders
Frequency Classification Not Known (Cannot be estimated from available data)

Safety Constraints and Time-Related Patterns

Official labeling includes explicit constraints and specific safety patterns for this medicine. The primary safety restriction is the contraindication against use in individuals with a known hypersensitivity to any of the five active substances—Arnica montana, Convallaria majalis, Crataegus, Digitalis purpurea, Kalium Carbonicum—or to any other component of the formulation.

A specific population safety consideration applies to the tablet formulation: individuals with galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption must observe caution, as the tablets contain lactose as an excipient.

Furthermore, official regulatory text for this product class may include a time-related safety pattern: the possibility of an initial temporary worsening of symptoms at the beginning of treatment. If this effect is observed, it is officially classified as a transient response to the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Пумпан is structured around the absence of documented toxicological events following excessive use. This is consistent with the product's classification as a highly diluted complex homeopathic medicinal product.


Documented Overdose Status

Entity Official Regulatory Statement
Documented Overdose Presentations None Documented. Official regulatory texts state that cases of overdose have not been registered.
Toxicological Expectation None Expected. Due to the very high dilutions of the active components, the official label notes that toxic or undesirable effects are not expected to be observed following an accidental or intentional overdose.
Emergency Actions Not Mandated for Overdose. No specific emergency response statements or procedures are provided in the context of an overdose. The general instruction is to discontinue use and consult a physician if any adverse reactions (e.g., hypersensitivity) occur.
Antidote / Treatment None Specified. The regulatory documentation does not list a specific antidote or provide detailed instructions for supportive treatment or monitoring requirements.

Regulatory Basis and Profile Summary

The entire overdose profile is defined by the official finding from national medicines authorities that overdose cases have not been registered to date. This regulatory status means the official labeling does not specify a list of overdose symptoms, severe outcomes, or procedural steps such as gastric lavage or monitoring requirements. There is no established severity classification. As a result, the regulatory documents do not define when immediate medical help must be sought based on a specific, drug-induced toxicological event, focusing instead on reporting known adverse reactions.

Therapeutic Uses of Пумпан

Quick Facts

  • Therapeutic Domain: May be used as an adjunct in the supportive care of certain cardiac conditions.
  • General Use: Utilized as a supplemental option in conventional treatment regimens.
  • Function: May help in the management of symptoms associated with ischemic heart disease and arterial hypertension.

Пумпан is a multi-component preparation intended for use as an adjunctive therapeutic strategy. It is commonly employed in the supportive care for individuals with certain cardiac conditions. The addition of this preparation to conventional treatment may have a role in managing symptoms associated with ischemic heart disease (IHD) and arterial hypertension (AH). In some instances, it is considered as an option for supplemental use alongside established medication protocols. Always consult with a healthcare professional for guidance on its appropriate use within a comprehensive treatment plan.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Пумпан — Official Regulatory Information

The official eligibility criteria for Пумпан are defined by regulatory authorities based on contraindications, age limits, and data sufficiency.

Absolute Contraindications (Do Not Use)

The medicine is strictly contraindicated for several populations, including:

  • Children under 12 years of age.
  • Patients with known hypersensitivity or allergy to any active or inactive component.
  • Individuals with unstable angina pectoris or decompensated acute/chronic heart failure.

Age and Condition-Based Restrictions

  • Pediatric Use: Use in children over 12 years is not recommended for the specific indications of arterial hypertension, ischemic heart disease, and heart failure due to a regulatory finding of insufficient data in this age group.
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is permitted, but requires caution as directed by the regulatory label.
  • Formulation-Specific Restrictions: The oral drops formulation requires caution for patients with alcoholism or severe liver/brain diseases due to its ethanol content, while the tablets are restricted for individuals with lactose intolerance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Пумпан, a multi-component complex homeopathic medicinal product, primarily documents the absence of clinically significant pharmacokinetic (PK) and pharmacodynamic (PD) interactions with conventional medicines. This structure is consistent with the regulatory classification of highly diluted preparations, for which official labels often state that specific interaction studies have not been performed or documented.

Absence of Formal Drug-Drug Interactions (DDI)

Official government labeling does not specify any interacting medicinal products or substance categories that would necessitate specific administration restrictions. There are no documented data regarding metabolic interactions (e.g., CYP-mediated effects) or drug transporter mechanisms that would alter the plasma concentration or clearance of co-administered drugs. Consequently, regulatory documents list no contraindicated combinations or mandatory timing separation rules for co-administration with other medicines.

Non-Pharmacological Interference

A general principle noted in the official regulatory documentation for this product class is a caution that the effectiveness of the preparation may be adversely affected by generally acting detrimental factors. This caution often references the consumption of alcohol or strong stimulants, such as coffee. This constitutes the primary interaction-related constraint defined within the official regulatory documents, though it is based on general homeopathic practice rather than a specific PK/PD risk assessment. No population-specific interaction cautions are officially documented.

Mechanism of Action

How Пумпан Works: Mechanistic Domains

Targeting Myocardial Contraction and Electrical Stability

The mechanism of action initiates at the cellular level, primarily through components that influence the Na^+/ K^+- ATPase enzyme in cardiac muscle. By inhibiting this key ion pump, the drug sets off a molecular cascade that increases intracellular calcium levels. This modulation of calcium handling results in a positive inotropic effect (enhanced force of contraction), while the action of the Potassium component contributes to the stability of myocardial electrical excitability.

Modulation of Vascular Tone and Circulatory Resistance

Another core domain involves the regulation of vascular smooth muscle tone, chiefly via components associated with the Nitric Oxide ( NO) signaling pathway. This modulation encourages the release of NO in the endothelium, promoting vasorelaxation across the peripheral and coronary circulation. The physiological outcome is a reduction in systemic vascular resistance (afterload), resulting in a reduction of the mechanical load on the heart.

Synergistic Action and Microcirculatory Pathway Modulation

The five active components act synergistically, influencing multiple interdependent parameters of hemodynamic function by combining increased cardiac force with reduced circulatory resistance. This effect is complemented by components that modulate the NF-kappa B pathway, contributing to the maintenance of microvascular integrity and fluid balance by modulating localized inflammatory mediator release. The highly diluted preparation is designed to act as a modulatory regulator across these multiple, interdependent physiological systems.

Dosage and Administration Information

The usage of Пумпан, described as a complex homeopathic preparation, is structured by a fixed-unit dosing protocol. The medicine is supplied as Oral Drops (Solution) and Tablets, establishing the oral route as the intended method of administration.

Standard administration involves a non-titrated, fixed unit dose. For adults and adolescents (12 years and older), the typical schedule requires taking 1 tablet or 10 drops per dose. The general use pattern indicates that the dose be repeated two or three times daily (BID or TID). In certain acute contexts, the product guidelines may permit a temporary, higher frequency of administration, such as every 30 minutes, for a short period.

Procedural guidelines for proper use often instruct that the medication be administered away from meals to prevent potential interference. Oral drops may be placed directly under the tongue (sublingually) or diluted in a small amount of water prior to consumption. Regarding the duration of use, guidelines define a condition-dependent period: use is continued until symptoms are relieved. If the condition persists or worsens after a short trial period (e.g., several days), the procedural instructions require consulting a healthcare professional.

Administration rules for children under 12 typically require the direct supervision of a healthcare provider. The dosage for this pediatric group, when specified, often equates to a fraction of the standard adult dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Пумпан


Evidence for Adjunctive Use in Ischemic Heart Disease (IHD) and Angina

Research has examined the supportive role of this preparation when used alongside standard medical treatments for Ischemic Heart Disease (IHD), specifically in adults experiencing stable angina. The preparation was evaluated in studies focused on conditions presenting with cycles of stability and flare-ups, such as stable angina. These studies were primarily composed of published clinical trials, though many involved relatively small sample sizes.

Researchers explored how symptoms evolved in the observed populations, with a focus on outcomes related to physical discomfort, such as tracking the number of anginal attacks reported by participants. The trials also monitored outcomes reflecting daily functioning or activity level, specifically measuring changes in exercise tolerance—for instance, how much physical work a patient could perform before symptoms appeared. Findings describe patterns observed in the studies over short-to-intermediate follow-up periods (around 7 to 11 weeks).


Evidence for Concomitant Use in Arterial Hypertension (AH)

The preparation was evaluated in studies focused on patients who had Arterial Hypertension (AH) that was co-occurring with their Ischemic Heart Disease. These studies research explored short-term symptom changes in this specific, defined patient group. Researchers monitored outcomes monitoring physiological strain or stress by tracking changes in Blood Pressure (BP) indices, sometimes utilizing 24-hour ambulatory monitoring.

Studies monitored the preparation's administration as a supplemental option alongside conventional anti-hypertensive drugs. The overall evidence base for complex homeopathic preparations in this area is characterized by methodological variability, and the evidence quality varies across studies when compared to the large-scale trials used to authorize conventional AH treatments.


What is Still Uncertain About the Research for Пумпан

Most studies that have evaluated this preparation have been short-term, typically observing responses over defined time intervals of less than three months. Because of this, long-term effects are not fully established. There is limited information for long-term outcomes regarding the sustained supportive function of the preparation. Furthermore, the sample sizes were modest in the focused trials, and comparative evidence is lacking in large-scale studies that directly compare the preparation against placebo or other therapies for its supportive role. This evidence highlights what is known — and what is still uncertain — about the preparation's application in various settings.

Frequently Asked Questions (FAQ)

Common questions about Пумпан (FAQ)

Q: Can I take Pumpan for a long time?

Official guidance describes that use is continued until symptoms are relieved. However, research studies have primarily focused on short-term to intermediate follow-up periods, typically less than three months. Therefore, official evidence concerning the safety or sustained effects of long-term use is not fully established.


Q: Is Pumpan the same as [name of another preparation]?

Official regulatory documents classify Pumpan as a multi-component complex homeopathic medicinal product. This means it contains a fixed combination of five specific active ingredients. This multi-component structure is a key defining factor that generally distinguishes it from single-component medications or other simpler preparation types.


Q: Can I drink Pumpan with alcohol?

Official regulatory documents include a caution that the preparation's effectiveness may be negatively influenced by generally detrimental factors, which specifically includes the consumption of alcohol. The official product information contains full details on this caution.


Q: Can I take Pumpan during pregnancy?

According to official regulatory information, the use of Pumpan during both pregnancy and breastfeeding is permitted. However, the regulatory label states that use during these periods is advised with caution.


Q: How does Pumpan affect the heartbeat?

The active components are described in official documents as influencing myocardial function. Specifically, they are associated with promoting a positive inotropic effect, which is an enhanced force of heart contraction, and contributing to the stability of the heart's electrical excitability.


Q: Is there a difference between Pumpan drops and tablets?

Both the drop and tablet forms contain the same five active ingredients. The main difference lies in the inactive components and related restrictions. The drops contain ethanol, which is advised with caution for patients with severe liver conditions, while the tablets contain lactose, which is a restriction for individuals with lactose intolerance.


Q: What does Pumpan do to the body?

Pumpan is officially classified as a cardiotonic and circulatory regulator. Its general purpose is to offer supportive and stabilizing effects specifically for the circulatory network, contributing to overall functional health.


Q: Does Pumpan help with blood pressure?

Research studies have evaluated the supportive role of this preparation in patients with arterial hypertension that co-occurred with ischemic heart disease. Researchers monitored changes in blood pressure indices in these specific patient groups. The mechanism is also described as reducing systemic vascular resistance, which lessens the mechanical load on the heart.


Q: Does Pumpan affect the liver or kidneys?

The oral drops formulation contains ethanol, and its use is advised with caution for patients with severe liver diseases. There are no direct restrictions or warnings noted in the official documentation concerning kidney function.


Q: What are the most common side effects of Pumpan?

According to the official safety profile, the most frequently documented adverse reactions are hypersensitivity reactions, which are allergic manifestations affecting the immune system and skin. The official frequency classification for these reactions is listed as Not Known, meaning it cannot be reliably estimated from available data.


Q: Should Pumpan be taken with or away from meals?

Official guidelines describe the administration of the medication as being away from meals. This separation is typically advised to prevent potential interference with the preparation's intended effect.


Q: What should I do if Pumpan hasn't helped after a week?

The official regulatory label states that if your condition persists or worsens after a short trial period, such as several days, the regulatory label requires consulting a healthcare professional.


Q: Can Pumpan cause drowsiness?

The official documented adverse reaction profile focuses primarily on hypersensitivity reactions (allergies). Drowsiness is not listed as a registered or known neurological adverse reaction in the official safety information for this preparation.


Q: Is it true that Pumpan is vitamins?

No, the official regulatory profile defines Pumpan as a complex homeopathic medicinal product. Its active components are derived from botanical and mineral origins, not from vitamins or dietary supplements.


Q: What dosage of Pumpan is considered normal?

Official administration guidelines describe the standard dosage for adults and adolescents (12 years and older) as a fixed unit dose taken multiple times throughout the day (two or three times daily). Consult the 'How to use' section for full dosage specifications.


Q: Does Pumpan treat the cause of the disease or just the symptoms?

The preparation is intended for supportive and stabilizing use specifically for the circulatory network. This classification aligns with a role in contributing to functional health and managing associated symptoms, rather than acting as a primary cure for underlying diseases.


Q: Are there scientific studies confirming the effect of Pumpan?

Official regulatory documents reference research studies that have examined the supportive role of the preparation in conditions like Ischemic Heart Disease and Arterial Hypertension. These studies focused on monitoring the evolution of patient symptoms and physiological outcomes.


Q: Is Pumpan compatible with antibiotics?

Official regulatory labeling primarily documents the absence of clinically significant pharmacokinetic and pharmacodynamic interactions with conventional medicines. Consequently, the documentation lists no specific contraindicated combinations with antibiotics.


Q: Can Pumpan cause dizziness?

The official documented adverse reaction profile focuses primarily on allergic hypersensitivity reactions. Dizziness is not listed as a registered or known neurological adverse reaction in the official safety information for this preparation.


Q: How does Pumpan interact with caffeine?

Official documentation includes a caution that the preparation's effectiveness may be negatively affected by generally detrimental factors, including strong stimulants such as coffee. The official product information contains guidance on this matter.


Q: Are there specific restrictions for the elderly when taking Pumpan?

Official documentation does not contain unique age-based restrictions or specific contraindications solely for the elderly population, beyond the general cautions that apply to all patient groups.


Q: Does Pumpan affect driving a car?

The safety profile documents adverse reactions primarily related to allergic hypersensitivity and does not list neurological or vision-related effects in its official warnings.


Q: Can I take Pumpan with painkillers?

Official regulatory labeling primarily documents the absence of clinically significant pharmacokinetic and pharmacodynamic interactions with conventional medicines, including painkillers. Therefore, the documentation lists no contraindicated combinations.


Q: When is the best time to take Pumpan – morning or evening?

Official usage guidance indicates that the fixed dose should be taken two or three times daily (BID or TID). The regulatory labeling does not specify a required time of day, such as morning or evening, focusing instead on consistent administration throughout the day.

How should Пумпан be stored and disposed of?

How to Store and Dispose of Пумпан?

Official regulatory guidelines define specific conditions for storing and discarding Пумпан (Oral Drops/Tablets) to maintain its stability.

Storage Conditions

Item Requirement
Temperature Store at a temperature not exceeding 25 C.
Container Must be stored in the original container; oral drops must be kept tightly closed.
Protection Protect from direct sunlight and high moisture. Do not freeze or refrigerate.
Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Discard any unused or expired product according to local regulatory requirements for pharmaceutical waste. The medicine must not be disposed of using wastewater or standard household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Пумпан found in:

A-Z Index: